| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001103682 |
| P356 | DOI | 10.1038/SJ.ONC.1208662 |
| P698 | PubMed publication ID | 15870696 |
| P5875 | ResearchGate publication ID | 7867175 |
| P50 | author | Frank Gannon | Q28741357 |
| Chin-Yo Lin | Q30347498 | ||
| Vladimir Benes | Q41125179 | ||
| Raphaël Métivier | Q42808659 | ||
| P2093 | author name string | Frank Gannon | |
| Edison T Liu | |||
| George Reid | |||
| Stefanie Denger | |||
| David Ibberson | |||
| Heike Brand | |||
| Tomi Ivacevic | |||
| P2860 | cites work | Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells | Q21184176 |
| RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer | Q24291637 | ||
| Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells | Q24672087 | ||
| Molecular basis of agonism and antagonism in the oestrogen receptor | Q27746278 | ||
| Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening | Q28210511 | ||
| Molecular determinants for the tissue specificity of SERMs | Q28211516 | ||
| MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin | Q28576622 | ||
| Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription | Q29547846 | ||
| Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen | Q29616224 | ||
| Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter | Q29616537 | ||
| Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability | Q29617252 | ||
| Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q29619251 | ||
| Estrogens and health in males | Q33951106 | ||
| Estrogens and estrogen-like non-feminizing compounds. Their role in the prevention and treatment of Alzheimer's disease. | Q34149018 | ||
| Etiology of Human Breast Cancer: A Review2 | Q34213087 | ||
| Polycystic ovarian syndrome in women with epilepsy: a review | Q34345051 | ||
| Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance | Q35123575 | ||
| A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence | Q38308285 | ||
| The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation | Q40690782 | ||
| Nucleosome positioning and transcription-associated chromatin alterations on the human estrogen-responsive pS2 promoter | Q41072437 | ||
| Early hormonal changes during valproate or carbamazepine treatment: a 3-month study | Q43705794 | ||
| Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy | Q43705798 | ||
| First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial | Q44146948 | ||
| Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy | Q44172530 | ||
| Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy | Q70513355 | ||
| Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy | Q71002444 | ||
| Associated effects of sodium butyrate on histone acetylation and estrogen receptor in the human breast cancer cell line MCF-7 | Q71290239 | ||
| Direct inhibition of the expression of cyclin D1 gene by sodium butyrate | Q71857913 | ||
| P433 | issue | 31 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| gene silencing | Q1431332 | ||
| P304 | page(s) | 4894-4907 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. | |
| P478 | volume | 24 |
| Q37656483 | A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy |
| Q37200466 | A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer |
| Q58214157 | A variant NuRD complex containing PWWP2A/B excludes MBD2/3 to regulate transcription at active genes |
| Q24294901 | A zinc finger HIT domain-containing protein, ZNHIT-1, interacts with orphan nuclear hormone receptor Rev-erbbeta and removes Rev-erbbeta-induced inhibition of apoCIII transcription |
| Q90239810 | Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma |
| Q37612400 | Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells |
| Q35840700 | Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes |
| Q39616031 | CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status |
| Q41511134 | Cohesin is required for expression of the estrogen receptor-alpha (ESR1) gene |
| Q35201384 | Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression |
| Q90390883 | Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise |
| Q33637251 | Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis |
| Q37797705 | DNA Demethylating Agents and Epigenetic Therapy of Cancer |
| Q37386851 | DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas |
| Q33962117 | DNA methylation of microRNA-375 in impaired glucose tolerance |
| Q36788512 | Development of histone deacetylase inhibitors for cancer treatment |
| Q36115426 | Differential estrogenic actions of endocrine-disrupting chemicals bisphenol A, bisphenol AF, and zearalenone through estrogen receptor α and β in vitro |
| Q34606452 | Dynamic interaction of HDAC1 with a glucocorticoid receptor-regulated gene is modulated by the activity state of the promoter |
| Q41129576 | E2-mediated cathepsin D (CTSD) activation involves looping of distal enhancer elements |
| Q26853549 | EGFR Amplification and Glioblastoma Stem-Like Cells |
| Q42012563 | Effects of trichostatin A on neuronal mu-opioid receptor gene expression |
| Q64974925 | Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. |
| Q28396626 | Endocrine-Disrupting Chemicals (EDCs): In Vitro Mechanism of Estrogenic Activation and Differential Effects on ER Target Genes |
| Q37830385 | Epigenetic aberrations during oncogenesis. |
| Q37962586 | Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance |
| Q52687717 | Estrogen-dependent control and cell-to-cell variability of transcriptional bursting. |
| Q28744012 | Fatty acids derived from royal jelly are modulators of estrogen receptor functions |
| Q39126183 | Functional assessment of MeCP2 in Rett syndrome and cancers of breast, colon, and prostate |
| Q34495315 | HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter |
| Q36912547 | HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade |
| Q24292915 | HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription |
| Q92504777 | HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms |
| Q42364933 | Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation |
| Q48150376 | Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. |
| Q34488424 | Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. |
| Q39573190 | Histone deacetylase 6 regulates estrogen receptor alpha in uterine leiomyoma |
| Q34503302 | Histone deacetylase 9 activates gamma-globin gene expression in primary erythroid cells |
| Q37097022 | Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines |
| Q28582424 | Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes |
| Q34152949 | Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis |
| Q24645148 | Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides |
| Q33705246 | Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling |
| Q37336908 | LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP |
| Q34417159 | Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? |
| Q38439266 | Mechanisms of aromatase inhibitor resistance. |
| Q33632070 | Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling |
| Q37962015 | Modulation of gene expression in ovarian cancer by active and repressive histone marks |
| Q33852615 | Motif-guided sparse decomposition of gene expression data for regulatory module identification |
| Q28743986 | Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model |
| Q35079955 | Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer |
| Q38969133 | Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. |
| Q34603086 | Research Resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant |
| Q40252452 | SET-mediated promoter hypoacetylation is a prerequisite for coactivation of the estrogen-responsive pS2 gene by PRMT1. |
| Q34942979 | SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. |
| Q47927498 | Targeting triple negative breast cancer with histone deacetylase inhibitors |
| Q46309280 | The Role of Sirtuins in Antioxidant and Redox Signaling |
| Q24300197 | The orphan nuclear receptor Rev-erbbeta recruits Tip60 and HDAC1 to regulate apolipoprotein CIII promoter |
| Q35067415 | The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene |
| Q47136713 | The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells. |
| Q33569444 | The short-chain fatty acid methoxyacetic acid disrupts endogenous estrogen receptor-alpha-mediated signaling |
| Q37454297 | Trans-regulation of histone deacetylase activities through acetylation |
| Q40005345 | Transient cyclical methylation of promoter DNA. |
| Q33889528 | Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein |
| Q64903545 | Weight Gain During Treatment of Bipolar Disorder (BD)—Facts and Therapeutic Options. |
Search more.